| Survival: | 10.1 months |
| Toxicity Grade: | 4 |
| Treatments: | Chemotherapy |
| Drugs: | Eloxatin |
| Country: | France |
| City/State/Province: | Villejuif |
| Hospital: | Institut Gustave Roussy |
| Journal: | Link |
| Date: | 1/2003 |
| Description: |
| Patients: This Phase II study involved 70 patients with malignant pleural mesothelioma; 51 men and 19 women. Fifty-five patients had not received prior chemotherapy. Treatment: The treatment consisted of the drug raltitrexed (tomudex) and the chemotherapy agent, oxaliplatin (eloxatin). Toxicity: Twenty patients withdrew from the treatment because of adverse events. There was one grade 4 event, asthenia. In addition, grade 3 toxicities included: nausea, paraesthesia, weight decrease, ALT and AST increase, vomiting, anorexia, hematologic, and abdominal pain. Results: Overall median survival was 32 weeks (7.4 months). Support: One or more of the study’s authors is affiliated with AstraZeneca, the manufacturer of tomudex. Correspondence: K. Fizazi, MD |